🔬 Antimicrobial Resistance Clinical Report

Neisseria gonorrhoeae Genomic Surveillance

Sample ID
FC428
Report Date
2025-12-10 03:20
Overall Risk Level
CRITICAL

🚨 FC428 CLONE DETECTED - CRITICAL ALERT

penA-60.001 allele (FC428) detected

📋 Executive Summary

Resistance Profile

✓ No major resistance markers detected - Likely susceptible to standard therapy

💊 Treatment Recommendation

Recommended Regimen

Resistance Profile: penA-60.001 present

First-line: Ceftriaxone + Azithromycin

Dose: 1-2g IM/IV + 2g PO

Second-line: Ceftriaxone + Gentamicin

Dose: 2g IM/IV + 240mg IM

Alternative: Ceftriaxone + Spectinomycin

Special Considerations: ID consult mandatory FC428 clone

Test of Cure: MANDATORY

🧬 Chromosomal Mutations Detected

No chromosomal mutations detected

🔄 Horizontally Acquired Resistance Genes (HGT/Plasmid-derived)

Plasmid-borne resistance genes acquired via horizontal gene transfer, rare but critical in N. gonorrhoeae

Gene Status Average Depth
blaTEM Not_detected 1.99
tetM Not_detected 0.00
ermB Not_detected 0.00
ermC Not_detected 0.00
ermF Not_detected 0.00
mefA Not_detected 0.00
Nm_sodC Detected 67.55

🔍 Molecular Typing

Marker Result Identity Significance
penA Allele penA_795 100.000% CHECK_MIC_TESTING
porB Allele NEIS1600_1163 100.000% Typing marker
mtrR Mosaic True 99.280% Efflux pump derepression

⚠️ Species Identification Warning

Neisseria meningitidis marker (Nm_sodC) detected

Possible co-infection, contamination, or misidentification. Repeat culture and identification.

Report generated by: AMR Profiler Workflow v2025.1

Reference: Based on WHO/CDC guidelines and PubMLST databases

© 2025 I Graviton, LLC. All rights reserved.
This report is for clinical and public health use only.

⚠️ Important: Treatment decisions should be made with medical provider, preferably incorporate phenotypic susceptibility testing when available and follow regional clinical guidelines. Genotypic resistance markers provide guidance but may not always correlate perfectly with phenotypic MICs.